SLDB•benzinga•
Looking Into Solid Biosciences's Return On Capital Employed
Summary
Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2022 by benzinga